Artificial immune cell treatment for melanoma aims for human trials in 2013 MedCity News NexImmune is an early stage biopharmaceutical company engineering artificial cells that can stimulate the immune system to treat cancer, transplant rejection, autoimmunity and infectious diseases. Its first candidate, AIM101, is intended for ... |
